| Literature DB >> 27911891 |
Mehmet Acikgoz1, M Sukru Paksu1, Ahmet Guzel1, Abdurrahman Alacam1, Fatma Alacam1.
Abstract
BACKGROUND We compared the factors that might impact the severity and the prognosis of carbamazepine (CBZ) intoxication in children, as well as the efficacy levels of the treatment options. MATERIAL AND METHODS Demographic information and clinical and laboratory findings for 40 patients were evaluated retrospectively. Predictive parameters for the development of serious complications were studied. RESULTS Median age of patients was 14 years; 65% of the patients were female. The most common pathological clinical finding and laboratory abnormality were inability to awaken the patient and hyperglycemia (45% and 60%, respectively). The incidences of convulsion, coma, and respiratory failure were 14 (35%), 10 (25%), and 3 (7.5%), respectively. The Glasgow Coma Scale (GCS) scores and pH levels at emergency service admission were significantly lower in the severe intoxication group and the ICU admission group, and body temperature and serum glucose and lactate levels were significantly higher in these groups. A significantly negative correlation was found between the serum CBZ level and the GCS score, but the serum CBZ level was found to be significantly positively correlated with the lactate level. CONCLUSIONS According to our study, the GCS score at admission to hospital, the serum CBZ, glucose, pH, and lactate levels, and body temperature might be useful in predicting serious CBZ intoxication and prognosis in pediatric cases. We conclude that invasive treatment methods, such as hemodialysis or albumin-enhanced continuous venovenous hemodialysis, should be used in patients who do not respond to supportive treatment.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27911891 PMCID: PMC5142583 DOI: 10.12659/msm.898899
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Demographic and clinical findings.
| 26 (65.0) | |
| Suicide | 34 (85) |
| Accidental | 6 (15) |
| 5 (0–24) | |
| 0–4 hour | 19 (47.5) |
| 5–8 hour | 11 (27.5) |
| >8 hour | 10 (25.0) |
| 60 (20–224) | |
| Drowsiness | 18 (45) |
| Vomiting | 17 (42.5) |
| Seizures | 14 (35) |
| Tachycardia | 8 (20) |
| Respiratory failure | 3 (7.5) |
| Hypotension | 5 (12.5) |
| Hypertension | 3 (7.5) |
| Fever | 3 (7.5) |
| Arrhythmia | 3 (7.5) |
| Urinary retention | 2 (5) |
| Bradycardia | 1 (2.5) |
| GCS ≤8 | 9 (22.5) |
| GCS (9–12) | 14 (35.0) |
| GCS (13–15) | 17 (42.5) |
| Mild | 11 (27.5) |
| Moderate | 17 (42.5) |
| High | 12 (30.0) |
| 19 (47.5) | |
| Convulsion | 14 (35.0) |
| Coma | 10 (25.0) |
| Distonik reaksiyon | 9 (22.5) |
| Respiratory failure | 3 (7.5) |
| Aritmia | 3 (7.5) |
| Ataxia | 3 (7.5) |
| Status epilepticus | 1 (2.5) |
| Hyperglycemia | 24 (60) |
| Acidosis | 17 (42.5) |
| Hyponatremia | 13 (32.5) |
| Hypokalemia | 10 (25) |
| Elevation of liver functions | 1 (2.5) |
| Gastric lavage | 32 (80) |
| Single dose activated charcoal | 6 (15) |
| Multiple dose activated charcoal | 26 (65) |
| Dialysis | 1 (2.5) |
| Mechanical ventilation | 3 (7.5) |
Comparison of clinical and laboratory findings in all patients according to the classification of carbamazepine toxisity.
| Mild (n=11) | Moderate (n=17) | Severe (n=12) | p | |
|---|---|---|---|---|
| Age | 13.8 (6–18) | 14 (1.5–17) | 15.5 (11–17) | 0.376 |
| Male/Female (ratio) | 4/7 | 8/9 | 2/10 | 0.238 |
| GCS | 13 (9–15)A | 11.5 (4–15)AB | 8 (3–15)B | 0.043 |
| SBP | 100 (80–120) | 112 (80–140) | 110 (57–120) | 0.056 |
| Body temperature | 36.0 (36–37.4)A | 36.5(36–38)B | 36.6 (36–40)B | 0.005 |
| Lactate level | 10.5 (8–30)A | 18 (6–98)AB | 27 (15–136)B | 0.016 |
| WBC Count | 9000 (6400–14900) | 9920 (7170–24600) | 10300 (6400–32100) | 0.666 |
| Blood Glucose | 93 (80–142)A | 115 (91–170)B | 133 (104–540)B | <0.001 |
| Sodium | 137 (133–142) | 134 (128–142) | 135 (128–138) | 0.108 |
| Potassium | 4.3 (3.3–4.6) | 3.8 (3.2–5.0) | 3.4 (2.5–5.1) | 0.054 |
| pH | 7.36 (7.32–7.41)A | 7.35 (7.21–7.42)AB | 7.28 (6.93–7.40)B | 0.016 |
Median (min–max);
GCS – Glasgow Coma Scale, SBP – systolic blood pressure; WBC – white blood cell
Comparison of the clinical and laboratory findings, according to whether the need for intensive care.
| Intensive Care Unit (n=18) | Emergency Service (n=22) | p | |
|---|---|---|---|
| Age | 15 (6–17) | 14 (1.5–18) | 0.916 |
| Male/Female (ratio) | 6/12 | 8/14 | 0.842 |
| GCS | 8.5 (3–15) | 14 (11–15) | <0.001 |
| SBP | 110 (57–140) | 100 (80–130) | 0.402 |
| Body temperature | 36.9 (36–40) | 36.2 (36–37.4) | 0.001 |
| Serum CBZ level | 30.5 (14.6–58) | 19.7 (12.5–35) | <0.001 |
| Lactate level | 26.5 (6–136) | 11.5 (8–128) | 0.008 |
| WBC Count | 10910 (6400–32100) | 9920 (6400–23660) | 0.663 |
| Blood Glucose | 121 (89–540) | 107 (80–170) | 0.105 |
| Sodium | 135 (128–139) | 135 (130–142)) | 0.150 |
| Potassium | 3.6 (2.5–4.6) | 4 (3.2–5.1) | 0.126 |
| pH | 7.30 (6.93–7.40) | 7.36 (7.28–7.42) | 0.008 |
Median (min–max);
GCS – Glasgow Coma Scale, SBP – systolic blood pressure; CBZ – carbamazepine, WBC – white blood cell.